
Bausch Health Companies Inc.
BHCNYSEHealthcareDrug Manufacturers - Specialty & Generic
Previous close
$6.44
−$0.37 · -5.43%
BHC company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
100
Deep Value
Momentum
28
Weakening
Sentiment
56
Mixed
Risk resilience
45
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteBausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- CA
- CEO
- Thomas J. Appio
- Listed since
- Mar 29, 1994
- Employees
- 20,300
Market position
Day range
Current $6.44
52-week range
Current $6.44
- Open
- $6.78
- Previous close
- $6.81
- Volume
- 3.97M
- 1.35× average
- Average volume
- 2.93M
- Average daily volume
- Market cap
- 2.41B USD
- Beta
- 0.38
- Market reference 1
- 50-day average
- $5.372
- +19.88% above average
- 200-day average
- $5.8575
- +9.94% above average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 22.46B USD
- P/E (TTM)
- -2.18×
- P/B (TTM)
- -1.36×
- P/S (TTM)
- 0.22×
- EV / EBITDA
- 7.07×
- Earnings yield
- 6.09%
- Free cash flow yield
- 38.91%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 71.82%
- Operating margin
- 25.44%
- Net margin
- -10.12%
- Return on equity
- -28.39%
- Return on assets
- 0.60%
- Return on invested capital
- 3.18%
Financial health
- Debt / equity
- -11.73×
- Current ratio
- 1.47×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 10.27B USD | 9.63B USD | 8.76B USD | 8.12B USD | 8.43B USD |
| Cost of goods sold | 3.01B USD | 2.78B USD | 2.56B USD | 2.36B USD | 2.39B USD |
| Gross profit | 7.25B USD | 6.84B USD | 6.2B USD | 5.76B USD | 6.04B USD |
| Research and development | 629M USD | 634M USD | 604M USD | 530M USD | 473M USD |
| Selling, general, and administrative | 3.44B USD | 3.28B USD | 2.9B USD | 2.53B USD | 2.49B USD |
| Operating expenses | 5.07B USD | 5.3B USD | 5.24B USD | 5.31B USD | 5.59B USD |
| Interest income | 48M USD | 33M USD | 26M USD | 14M USD | 7M USD |
| Interest expense | 1.6B USD | 1.39B USD | 1.33B USD | 1.46B USD | 1.43B USD |
| Depreciation and amortization | 1.21B USD | 1.27B USD | 1.26B USD | 1.39B USD | 1.55B USD |
| Operating income | 2.19B USD | 1.55B USD | 963M USD | 454M USD | 450M USD |
| Net income | 157M USD | −46M USD | −592M USD | −225M USD | −948M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 45%
- 5 beats, 6 misses, 0 met estimates
- Average EPS surprise
- -3.53%
- 11 comparable reports
- Latest EPS result
- 1.26
- Estimate 0.96 · Beat by 31.25%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Analyst price target
Average target
$9.83
52.64% upsideRecent analyst actions
BHC news
Corporate actions
Annual dividends per share
Cash distributions grouped by calendar year; partial years are marked.
$1.28
2010 complete year+156.0% since 2006
$0.50
2,006
$2.00
2,007
$1.50
2,008
$0.645
2,009
$1.28
2,010
Corporate action history
| Action | Ex-dividend date | Details | Record date | Payment date |
|---|---|---|---|---|
Dividend | Nov 10, 2010 | $1.00Quarterly | Nov 15, 2010 | Dec 22, 2010 |
Dividend | Aug 30, 2010 | $0.095Quarterly | Sep 1, 2010 | Oct 4, 2010 |
Dividend | May 28, 2010 | $0.095Quarterly | Jun 2, 2010 | Jul 5, 2010 |
Dividend | Mar 4, 2010 | $0.09Quarterly | Mar 8, 2010 | Apr 5, 2010 |
Dividend | Nov 30, 2009 | $0.09Quarterly | Dec 2, 2009 | Jan 4, 2010 |
Dividend | Aug 28, 2009 | $0.09Quarterly | Sep 1, 2009 | Oct 5, 2009 |
Ex-dividend Nov 10, 2010
$1.00
Quarterly
Record Nov 15, 2010 · Payment Dec 22, 2010
Ex-dividend Aug 30, 2010
$0.095
Quarterly
Record Sep 1, 2010 · Payment Oct 4, 2010
Ex-dividend May 28, 2010
$0.095
Quarterly
Record Jun 2, 2010 · Payment Jul 5, 2010
Ex-dividend Mar 4, 2010
$0.09
Quarterly
Record Mar 8, 2010 · Payment Apr 5, 2010
Ex-dividend Nov 30, 2009
$0.09
Quarterly
Record Dec 2, 2009 · Payment Jan 4, 2010
Ex-dividend Aug 28, 2009
$0.09
Quarterly
Record Sep 1, 2009 · Payment Oct 5, 2009
BHC peers
ETFs holding BHC
Funds reporting this stock among their holdings, ordered by reported position size.
Dimensional - International Small Cap ETFDFIS2.27M0.04%5.91B USD0.39%$37.545+0.71%
Dimensional - International Small Cap Value ETFDISV1.46M0.03%5.23B USD0.42%$44.49+0.86%
Dimensional - International Core Equity 2 ETFDFIC1.46M0.01%15.43B USD0.22%$39.405+0.83%
VanEck Pharmaceutical ETFPPH1.36M0.13%1.07B USD0.36%$116.63+1.35%
Invesco RAFI Developed Markets ex-U.S. ETFPXF781.12K0.03%3B USD0.43%$79.77+0.90%
Dimensional World ex U.S. Core Equity 2 ETFDFAX682.57K0.01%12.57B USD0.28%$38.16+0.82%
Dimensional - International Core Equity Market ETFDFAI209.88K0.00%18.23B USD0.18%$43.35+0.81%
Dimensional International Sustainability Core 1 ETFDFSI139.84K0.01%1.19B USD0.24%$47.365+0.78%
Dimensional - International Small Cap ETFDFIS- Market value
- 2.27M
- Weight
- 0.04%
- AUM
- 5.91B USD
- Expense ratio
- 0.39%
- Price / 1D
- $37.545+0.71%
Dimensional - International Small Cap Value ETFDISV- Market value
- 1.46M
- Weight
- 0.03%
- AUM
- 5.23B USD
- Expense ratio
- 0.42%
- Price / 1D
- $44.49+0.86%
Dimensional - International Core Equity 2 ETFDFIC- Market value
- 1.46M
- Weight
- 0.01%
- AUM
- 15.43B USD
- Expense ratio
- 0.22%
- Price / 1D
- $39.405+0.83%
VanEck Pharmaceutical ETFPPH- Market value
- 1.36M
- Weight
- 0.13%
- AUM
- 1.07B USD
- Expense ratio
- 0.36%
- Price / 1D
- $116.63+1.35%
Invesco RAFI Developed Markets ex-U.S. ETFPXF- Market value
- 781.12K
- Weight
- 0.03%
- AUM
- 3B USD
- Expense ratio
- 0.43%
- Price / 1D
- $79.77+0.90%
Dimensional World ex U.S. Core Equity 2 ETFDFAX- Market value
- 682.57K
- Weight
- 0.01%
- AUM
- 12.57B USD
- Expense ratio
- 0.28%
- Price / 1D
- $38.16+0.82%
Dimensional - International Core Equity Market ETFDFAI- Market value
- 209.88K
- Weight
- 0.00%
- AUM
- 18.23B USD
- Expense ratio
- 0.18%
- Price / 1D
- $43.35+0.81%
Dimensional International Sustainability Core 1 ETFDFSI- Market value
- 139.84K
- Weight
- 0.01%
- AUM
- 1.19B USD
- Expense ratio
- 0.24%
- Price / 1D
- $47.365+0.78%
Continue in GoAI
Research BHCresearch.disclaimer











